Brief: BioCorRx Submits Fast Track Application To FDA For Bicx104, An Implantable Biodegradable Naltrexone Pellet For The Treatment Of Opioid Use Disorder
18/07/2023 14:15
July 18 (Reuters) - BioCorRx Inc BICX.PK :
* BIOCORRX SUBMITS FAST TRACK APPLICATION TO FDA FOR
BICX104, AN
IMPLANTABLE BIODEGRADABLE NALTREXONE PELLET FOR THE TREATMENT OF
OPIOID USE DISORDER
Source text for Eikon: ID:nGNX38N7D3
Further company coverage: BICX.PK
Recent news on Biocorrx
See all newsBrief: BioCorRx Submits Fast Track Application To FDA For Bicx104, An Implantable Biodegradable Naltrexone Pellet For The Treatment Of Opioid Use Disorder
Brief: Biocorrx Announces Completion Of Treatment Phase Of Study Subjects And Preliminary Safety Data From Phase I Clinical Trial Of Bicx104
Brief: BioCorRx Partners With Government Plus To Expand Its Beat Addiction Recovery Program In The United States
Brief: Biocorrx Completes Final Subject Enrollment In Phase I Clinical Trial Of Bicx104, An Implantable Naltrexone Pellet For The Treatment Of Opioid Use Disorder
Brief: BioCorRx Begins Recruitment for Clinical Trial of BICX104